Nov 17 (Reuters) – Merck said on Tuesday it would stop development of its experimental blood cancer drug, nemtabrutinib, after a review found the treatment’s benefits may not outweigh its risks.
An independent monitoring committee reached that conclusion after reviewing results from a late-stage study of the drug. Merck said its review of the full data confirmed the finding.
The drugmaker did not disclose what risks were found. It did not immediately respond to a Reuters request for comment.
The company will also discontinue two other late-stage trials of the drug. The oral drug was being evaluated for chronic lymphocytic leukemia and other blood cancers.
The analyses are ongoing and the results will be shared with the scientific community, it said.
(Reporting by Kunal Das in Bengaluru; Editing by Sahal Muhammed)

